The Health Care Leaders in 's 40 Under 40

Hello and happy hump day, readers!

This morning, Fortune came out with its latest list of the 40 entrepreneurs, leaders, and iconoclasts who are still "under the hill"—our 2019 40 Under 40. And, as luck would have it, it features some fascinating health care-focused talent.

That includes Mei Mei Hu, the co-founder and CEO of United Neuroscience, whose company is trying to make an Alzheimer's vaccine; Trevor Martin, the wunderkind isn't just under 40, but barely 30 and taking a new approach to CRISPR gene-editing tech; and Keller Rinaudo, whose drone company is doing something that's approximately the opposite of the things one might associate with drones.

The entire list is great and well worth your time. I hope you browse through it.

Read on for the day's news.

Sy Mukherjee, @the_sy_guy, [email protected]

DIGITAL HEALTH

Former Illumina accountant charged in insider trading scheme. The Securities and Exchange Commission (SEC) has filed insider trading charges against a former accountant at the genetic sequencing powerhouse Illumina for allegedly tipping off her friend (also named in the complaint) about quarterly earnings. In return, the complaint says, the accountant would receive all-expense paid travel and other such gifts; the scheme allegedly generated some $6.2 million in profits. (SEC)

INDICATIONS

As EpiPen shortage drags, Novartis to sell generic allergy shot. Remember the EpiPen shortage—linked to both generic drug giant Mylan and its manufacturing partner Pfizer? It’s still going strong, and it’s giving other major pharmaceutical companies an opening to get in on the market. The latest is Switzerland’s Novartis, whose generic unit Sandoz will now launch its own EpiPen alternative, Symjepi, in pharmacies following an initial move to make it available to hospitals. And it’s undercutting the price of Mylan’s “authorized generic” version of the EpiPen by $50. (Reuters)

THE BIG PICTURE

Study: Stop with the supplements, eat actual food. A massive meta-analysis of diet and nutrition supplements comes to a conclusion some public health experts have been trumpeting for years: Overall, many dietary changes and dietary supplements at large don’t actually do anything. In fact, there may even be some overall harm to taking certain supplements. There is, however, some nuance: “Reduced salt intake, omega-3 LC-PUFA use, and folate supplementation could reduce risk for some cardiovascular outcomes in adults. Combined calcium plus vitamin D might increase risk for stroke,” the study authors wrote. (Gizmodo)

REQUIRED READING

40 Under 40: Advice That Helped Them Get Aheadby Megan Arnold

How Millennials Are Changing the Face of Leadershipby Ed Frauenheim

Designing a Welcoming Corporate Cultureby Ellen McGirt

Visa Pours Millions into Cryptocurrency Startup Anchorageby Robert Hackett

Find past coverage. Sign up for other Fortune newsletters.

0 Comment

NO COMMENTS

Comments are closed.